文献速递脊柱外科

胰高血糖素样肽-1受体激动剂药物改变脊柱手术结局:一项超过15,000名患者的研究

Glucagon-Like Peptide-1 Receptor Agonist Medications Alter Outcomes of Spine Surgery: A Study Among Over 15,000 Patients.
PubMed 文献 · Spine (Phila Pa 1976) · 2025-02-03

该回顾性多中心队列研究基于TriNetX数据库,纳入2008年至2022年接受脊柱融合术的糖尿病患者,经倾向性评分匹配后分析2263例,其中1560例为肥胖。围手术期使用GLP-1受体激动剂与术后感染、翻修手术、再入院及活动异常率降低相关,骨折率无显著差异。作者认为GLP-1受体激动剂可能是有价值的辅助治疗,需进一步前瞻性和动物研究证实。

要点

  • 肥胖患者中,GLP-1受体激动剂使用与术后感染风险降低相关(HR=0.168)。
  • 肥胖患者中,GLP-1受体激动剂使用与翻修手术风险降低相关(HR=0.505)。
  • 非肥胖患者中,GLP-1受体激动剂使用与再入院风险降低相关(HR=0.241)。

核心结论

  • 在脊柱融合患者中,GLP-1受体激动剂使用与术后结局改善相关,包括感染率降低、翻修手术减少及生活质量指标改善。
  • 作者认为GLP-1受体激动剂可能是管理接受脊柱融合的糖尿病和肥胖患者手术结局的有价值辅助治疗。
  • 作者指出需要进一步的前瞻性和动物基础研究来证实这些发现并探索潜在机制。

研究设计与样本

  • 研究设计为回顾性队列研究,采用多中心TriNetX平台研究数据库。
  • 研究对象为2008年至2022年间接受脊柱融合术的糖尿病患者,根据体重指数和GLP-1受体激动剂使用情况建立队列。
  • 采用倾向性评分匹配,使用体重指数、糖化血红蛋白、手术干预及其他人口学特征创建平衡队列。
  • 匹配后研究队列共2263例患者,其中1560例归类为肥胖。

主要发现

  • GLP-1受体激动剂使用与术后感染率显著降低相关:肥胖组HR=0.168(0.086,0.328),非肥胖组HR=0.250(0.102,0.612)。
  • GLP-1受体激动剂使用与翻修手术减少相关:肥胖组HR=0.505(0.368,0.693),非肥胖组HR=0.439(0.272,0.708)。
  • GLP-1受体激动剂使用与术后再入院率降低相关:肥胖组HR=0.283(0.243,0.329),非肥胖组HR=0.241(0.193,0.301)。
  • GLP-1受体激动剂使用与活动异常减少相关:肥胖组HR=0.355(0.230,0.549),非肥胖组HR=0.508(0.269,0.959)。
  • GLP-1受体激动剂使用者与非使用者之间骨折率无显著差异。

局限性

  • 作者指出需要进一步的前瞻性和动物基础研究来证实这些发现并探索潜在机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: Retrospective cohort study. OBJECTIVE: To investigate the relationship between perioperative glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and postoperative outcomes after spinal fusion in obese and diabetic patient populations. BACKGROUND: GLP-1 RAs have been shown to be beneficial when used perioperatively in clinical orthopedic arthroplasty literature. Minimal evidence exists showing efficacy with respect to spinal fusion. MATERIALS AND METHODS: This retrospective, multi-center study accessed the TriNetX platform, using the research database to identify diabetic patients who underwent spinal fusion between 2008 and 2022. Cohorts were created based on body mass index and GLP-1 RA usage. Propensity score matching was employed to create balanced cohorts utilizing body mass index, hemoglobin A1c, surgical intervention, as well as other demographic characteristics. Orthopedic outcomes were compared between GLP-1 RA users and non-users. The primary outcomes included postoperative infection, readmission, revision surgery, and quality of life metrics. RESULTS: After matching, the study cohort consisted of 2263 patients, with 1560 classified as obese. GLP-1 RA use was associated with significantly reduced postoperative infection rates [obese: HR = 0.168 (0.086, 0.328), not obese: HR = 0.250 (0.102, 0.612)], fewer revisions [obese: HR = 0.505 (0.368, 0.693), not obese: HR = 0.439 (0.272, 0.708)], decreased postoperative readmission rates [obese: HR = 0.283 (0.243, 0.329), not obese: HR = 0.241 (0.193, 0.301)], and reduced mobility abnormalities [obese: HR = 0.355 (0.230, 0.549), not obese: HR = 0.508 (0.269, 0.959)]. No significant differences were observed in rates of fracture rates between GLP-1 RA users and non-users. CONCLUSIONS: GLP-1 RA use in spinal fusion patients was associated with improved postoperative outcomes, including lower infection rates, fewer revisions, and better quality of life metrics. These findings suggest that GLP-1 RAs may be a valuable adjunctive therapy in managing surgical outcomes in diabetic and obese patients undergoing spinal fusion. Further prospective and animal-based studies are needed to confirm these findings and explore the underlying mechanisms.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Wiener JM, Sanghvi PA, Vlastaris K, et al. Glucagon-Like Peptide-1 Receptor Agonist Medications Alter Outcomes of Spine Surgery: A Study Among Over 15,000 Patients. Spine (Phila Pa 1976). 2025. PMID: 39895110. doi:10.1097/BRS.0000000000005283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。